The weight loss drug market is entering a more complicated phase, and three recent reports suggest the winners may be decided as much by molecular design and price as by raw efficacy.
According to Endpoints News, Eli Lilly's triple agonist retatrutide — nicknamed the "triple-G" — looks like the most effective obesity drug to reach late-stage trials, with weight loss of up to 25% in Phase 3. That kind of number attracts attention, and not all of it from patients with prescriptions.
Endpoints reports that the drug's promise has fueled a gray market in unapproved versions. A new study found that people using those gray-market copies achieved relatively poor weight loss compared with the trial results. In other words, buying something labeled as the most powerful obesity drug available does not mean getting the thing that was actually tested.
Meanwhile, a second front is opening around amylin, a hormone drugmakers are pairing with GLP-1 agonists. Endpoints News reports that Novo Nordisk's CagriSema is likely to become the first approved drug combining an amylin analog with a GLP-1 agonist later this year, and that drug design is emerging as a key differentiator in the category. Lilly's own crucial mid-stage amylin data is approaching.
But the science may not settle it. BioPharma Dive reports that as Lilly and Novo Nordisk race for market share, surveys point to affordability and doctors' prescribing preferences as factors that could help decide which company wins.
Why it matters: these drugs are among the most consequential medicines of the decade, and this story is a reminder that what patients actually get depends on supply chains, cost, and prescribing habits — not just what worked in a trial.